12:00 AM
 | 
Mar 26, 2007
 |  BioCentury  |  Emerging Company Profile

ProFibrix: Hemostatic sprinkles

The market for hemostatic products is getting increasingly crowded. But so far these products are sold primarily as powders or frozen liquid, both of which must be prepared for use in liquid form. Since severe bleeding can be an unexpected event, ProFibrix B.V. thinks its Fibrocaps dry powder fibrin sealant may have a competitive advantage, since it can be used off the shelf as a powder without rehydrating.

On Monday this week, the company was expected to announce an E8.5 million ($11 million) series A round.

Preclinical testing has shown that Fibrocaps powder, which contains fibrinogen and thrombin derived from human plasma, is as effective as marketed fibrin sealants at stopping bleeding, CEO and co-founder Jaap Koopman told BioCentury. The company has tested the powder in animal models of liver and spleen surgery and traumatic injury.

GMP manufacturing for Fibrocaps is in development and Phase I/II testing is expected...

Read the full 743 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >